Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 131, Issue 25
June 21 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS
Drawing the line of ineligibility
Clinical Trials & Observations
Anita J. Kumar
View Articletitled, Drawing the line of ineligibility
Lymphoid Neoplasia
Shielding p53 from destruction
Deepa Sampath
View Articletitled, Shielding p53 from destruction
THROMBOSIS AND HEMOSTASIS
Warfarin, a juggler’s demise
Laurent O. Mosnier
View Articletitled, Warfarin, a juggler’s demise

SPECIAL REPORT

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Clinical Trials & Observations
Michael Hallek,Bruce D. Cheson,Daniel Catovsky,Federico Caligaris-Cappio,Guillermo Dighiero,Hartmut Döhner,Peter Hillmen,Michael Keating,Emili Montserrat,Nicholas Chiorazzi,Stephan Stilgenbauer,Kanti R. Rai,John C. Byrd,Barbara Eichhorst,Susan O’Brien,Tadeusz Robak,John F. Seymour,Thomas J. Kipps
View Articletitled, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

REVIEW ARTICLE

Biology and treatment of Richter syndrome
Clinical Trials & Observations
Davide Rossi,Valeria Spina,Gianluca Gaidano
View Articletitled, Biology and treatment of Richter syndrome

HOW I TREAT

How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions
Clinical Trials & Observations
France Pirenne,Karina Yazdanbakhsh
View Articletitled, How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies
Clinical Trials & Observations
Abby Statler,Megan Othus,Harry P. Erba,Thomas R. Chauncey,Jerald P. Radich,Steven Coutre,Anjali Advani,Sucha Nand,Farhad Ravandi,Sudipto Mukherjee,Mikkael A. Sekeres
View Articletitled, Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies
Supplemental data

LYMPHOID NEOPLASIA

TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma
Alexander Jethwa,Mikołaj Słabicki,Jennifer Hüllein,Marius Jentzsch,Vineet Dalal,Sophie Rabe,Lena Wagner,Tatjana Walther,Wolfram Klapper,MMML Network Project,Hanibal Bohnenberger,Mandy Rettel,Junyan Lu,Arne H. Smits,Frank Stein,Mikhail M. Savitski,Wolfgang Huber,Yael Aylon,Moshe Oren,Thorsten Zenz
View Articletitled, TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma
Supplemental data
TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia
Jun Yang,Francis R. LeBlanc,Shubha A. Dighe,Cait E. Hamele,Thomas L. Olson,David J. Feith,Thomas P. Loughran, Jr
View Articletitled, TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia
Supplemental data

MYELOID NEOPLASIA

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
Clinical Trials & Observations
Sanjay S. Patel,Frank C. Kuo,Christopher J. Gibson,David P. Steensma,Robert J. Soiffer,Edwin P. Alyea, III,Yi-Bin A. Chen,Amir T. Fathi,Timothy A. Graubert,Andrew M. Brunner,Martha Wadleigh,Richard M. Stone,Daniel J. DeAngelo,Valentina Nardi,Robert P. Hasserjian,Olga K. Weinberg
View Articletitled, High <em>NPM1</em>-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
Supplemental data

THROMBOSIS AND HEMOSTASIS

Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase
Mark A. Rishavy,Kevin W. Hallgren,Lee Wilson,Savita Singh,Kurt W. Runge,Kathleen L. Berkner
View Articletitled, Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase
Supplemental data

TRANSPLANTATION

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease
Clinical Trials & Observations
Myrna R. Nahas,Robert J. Soiffer,Haesook T. Kim,Edwin P. Alyea, III,Jon Arnason,Robin Joyce,Joseph H. Antin,Vincent T. Ho,Dina Stroopinsky,Shuli Li,James D. Levine,Malgorzata McMasters,Salvia Jain,Ayad Hamdan,Dimitrios Tzachanis,Mary Paty Bryant,Emma K. Logan,Josie Bazemore,Jeremy Stewart,Amy Joyce,Susan Stephenson,Abigail Washington,Leandra Cole,Athalia Pyzer,Rebecca Karp Leaf,David E. Avigan,Jacalyn Rosenblatt
View Articletitled, Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease
Supplemental data
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
CME Clinical Trials & Observations
Hannah Major-Monfried,Anne S. Renteria,Attaphol Pawarode,Pavan Reddy,Francis Ayuk,Ernst Holler,Yvonne A. Efebera,William J. Hogan,Matthias Wölfl,Muna Qayed,Elizabeth O. Hexner,Kitsada Wudhikarn,Rainer Ordemann,Rachel Young,Jay Shah,Matthew J. Hartwell,Mohammed S. Chaudhry,Mina Aziz,Aaron Etra,Gregory A. Yanik,Nicolaus Kröger,Daniela Weber,Yi-Bin Chen,Ryotaro Nakamura,Wolf Rösler,Carrie L. Kitko,Andrew C. Harris,Michael Pulsipher,Ran Reshef,Steven Kowalyk,George Morales,Ivan Torres,Umut Özbek,James L. M. Ferrara,John E. Levine
View Articletitled, MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
Supplemental data

LETTERS TO BLOOD

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma
Clinical Trials & Observations
Guillaume Manson,Charles Herbaux,Pauline Brice,Krimo Bouabdallah,Aspasia Stamatoullas,Jean-Marc Schiano,Hervé Ghesquieres,Laurent Dercle,Roch Houot,on behalf of the Lymphoma Study Association
View Articletitled, Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma
A common TCN1 loss-of-function variant is associated with lower vitamin B12 concentration in African Americans
Yao Hu,Laura M. Raffield,Linda M. Polfus,Arden Moscati,Girish Nadkarni,Michael H. Preuss,Xue Zhong,Qiang Wei,Stephen S. Rich,Yun Li,James G. Wilson,Adolfo Correa,Ruth J. F. Loos,Bingshan Li,Paul L. Auer,Alex P. Reiner,the NHLBI Trans-Omics for Precision Medicine Consortium
View Articletitled, A common <em>TCN1</em> loss-of-function variant is associated with lower vitamin B<sub>12</sub> concentration in African Americans
Supplemental data
Plerixafor effectively mobilizes CD56bright NK cells in blood, providing an allograft predicted to protect against GVHD
Peggy P. C. Wong,Amina Kariminia,David Jones,Connie J. Eaves,Ronan Foley,Sabine Ivison,Stephen Couban,Kirk R. Schultz
View Articletitled, Plerixafor effectively mobilizes CD56<sup>bright</sup> NK cells in blood, providing an allograft predicted to protect against GVHD

BLOOD WORK

Visceral leishmaniasis presenting with pancytopenia and circulating blastlike lymphocytes
Nada P. Assaf,Zaher I. Chakhachiro
View Articletitled, Visceral leishmaniasis presenting with pancytopenia and circulating blastlike lymphocytes
HHV8-associated lymphoproliferative disorder in the peripheral blood
Charles Manogaran,Shireen Kassam
View Articletitled, HHV8-associated lymphoproliferative disorder in the peripheral blood

ERRATUM

Caserta E, Chea J, Minnix M, et al. Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood. 2018;131(7):741-745.
View Articletitled, Caserta E, Chea J, Minnix M, et al. Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. <em>Blood</em>. 2018;131(7):741-745.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Biomarkers predict outcomes for resistant GVHD
CME
View Articletitled, Biomarkers predict outcomes for resistant GVHD
All Issues

Advertisement

Data mining for second malignancies after CAR-T
Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
MRD and EFS in pediatric T-lymphoblastic lymphoma
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement